Shorted
Clinuvel Pharmaceuticals logo
CUV
Pharmaceuticals, Biotechnology & Life Sciences

Clinuvel Pharmaceuticals

Short interest
9.07%
+0.95 pp 30d
as of 9 Oct 2026
Reported shorts
4.6M
Shares on issue
50.487M

Clinuvel Pharmaceuticals (CUV) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Positive
6 Oct

Can Clinuvel's Vitiligo Cases Lift Sentiment (ASX:CUV)?

Highlights Clinuvel presented new vitiligo patient cases at the European dermatology congress. All of the patients showed repigmentation, which continued after treatment stopped. Top-line results from the vitiligo study are due in December. Clinuvel Pharmaceuticals (ASX:CUV) is drawing fresh attention after presenting new patient cases from its vitiligo study at the European Academy of Dermatology and Venereology congress in Vienna late last week, giving the market a preview ahead of top-line...

Continue reading
Kalkine
Positive
1 Oct

Could Clinuvel (ASX:CUV) Unlock Value by Moving to the Nasdaq?

Highlights Clinuvel plans to delist from the ASX and list all its ordinary shares on the Nasdaq from the start of next year. The final quarter of the calendar year, which begins today, is the window flagged for its vitiligo study readout. The company remains profitable and debt-free, but US competition in its core market has weighed on sentiment. Clinuvel Pharmaceuticals (ASX:CUV) enters the final quarter of the calendar year today with a pivotal stretch ahead, as the photomedicine company pr...

Continue reading
Kalkine
Neutral
28 Sept

What next for Clinuvel (ASX:CUV) as its vitiligo readout nears?

Highlights Clinuvel has unveiled a proprietary single-use administration device for its controlled-release formulations. Topline results from its first late-stage vitiligo study are expected before the end of the calendar year. A fresh notice of a new major owner on the register and annual meeting timing keep the stock in focus. Clinuvel (ASX:CUV) enters the final quarter of the calendar year with a busy run of catalysts, after the specialist dermatology drug developer unveiled its proprietar...

Continue reading
Kalkine
Neutral
9 Sept

Clinuvel Adds Weight to Execution Pathway (ASX:CUV)

Highlights Clinuvel Pharmaceuticals has placed execution pathway at the centre of current equity attention through its new release. The update directs attention toward funding access, milestone delivery and trading liquidity without removing the need for careful evidence review. Trading assessment depends on delivery quality, clear reporting and alignment between strategy, funding and operating conditions. Clinuvel Pharmaceuticals (ASX:CUV) has drawn attention during the latest completed Aust...

Continue reading
Kalkine
Positive
11 Aug

What Now for Clinuvel (ASX:CUV) on Specialist Medicine Growth?

Highlights Clinuvel remains in focus as investors assess the current operating outlook through operating progress, a key indicator of whether current momentum can translate into durable operating progress. August reporting season is sharpening attention on revenue visibility and cost control, helping investors distinguish headline activity from the underlying quality of the business outlook. A key risk is that thin trading can exaggerate short-term sentiment, which could weaken confidence in th...

Continue reading